Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
Authors:
- Elsie M F HorneEHElsie M F Horne
- William J HulmeWHWilliam J Hulme
- Ruth H KeoghRKRuth H Keogh
- Tom M PalmerTPTom M Palmer
- Elizabeth J WilliamsonEWElizabeth J Williamson
- Edward P K ParkerEPEdward P K Parker
- Amelia GreenAGAmelia Green
- Venexia WalkerVWVenexia Walker
- Alex J WalkerAWAlex J Walker
- Helen CurtisHCHelen Curtis
- Louis FisherLFLouis Fisher
- Brian MacKennaBMBrian MacKenna
Open Access
Abstract
Objective To estimate waning of covid-19 vaccine effectiveness over six months after second dose. Design Cohort study, approved by NHS England. Setting Linked primary care, hospital, and covid-19 records within the OpenSAFELY-TPP database. Participants Adults without previous SARS-CoV-2 infection were eligible, excluding care home residents and healthcare professionals. Exposures People who had received two doses of BNT162b2 or ChAdOx1 (administered during the national vaccine rollout) were compared with unvaccinated people during six consecutive comparison periods, each of four weeks. Main outcome measures Adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, positive SARS-CoV-2 test, and non-covid-19 related death comparing vaccinated with unvaccinated people. Waning vaccine effectiveness was quantified as ratios of adjusted hazard ratios per four week period, separately for subgroups aged ≥65 years, 18-64 years and clinically vulnerable, 40-64 years, and 18-39 years. Results 1 951 866 and 3 219 349 eligible adults received two doses of BNT162b2 and ChAdOx1, respectively, and 2 422 980 remained unvaccinated. Waning of vaccine effectiveness was estimated to be similar across outcomes and vaccine brands. In the ≥65 years subgroup, ratios of adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test ranged from 1.19 (95% confidence interval 1.14 to 1.24)to 1.34 (1.09 to 1.64) per four weeks. Despite waning vaccine effectiveness, rates of covid-19 related hospital admission and death were substantially lower among vaccinated than unvaccinated adults up to 26 weeks after the second dose, with estimated vaccine effectiveness ≥80% for BNT162b2, and ≥75% for ChAdOx1. By weeks 23-26, rates of positive SARS-CoV-2 test in vaccinated people were similar to or higher than in unvaccinated people (adjusted hazard ratios up to 1.72 (1.11 to 2.68) for BNT162b2 and 1.86 (1.79 to 1.93) for ChAdOx1). Conclusions The rate at which estimated vaccine effectiveness waned was consistent for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test and was similar across subgroups defined by age and clinical vulnerability. If sustained to outcomes of infection with the omicron variant and to booster vaccination, these findings will facilitate scheduling of booster vaccination.Keywords
All Related Versions
Funding Information
- NIHR Bristol Biomedical Research Centre
- Health Foundation
- UK Research and Innovation
- Medical Research Council
This publication has 28 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care SettingsNew England Journal of Medicine, 2021
- Covid-19 Vaccine Effectiveness and the Test-Negative DesignNew England Journal of Medicine, 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantNew England Journal of Medicine, 2021
- Impact of vaccination on new SARS-CoV-2 infections in the United KingdomNature Medicine, 2021
- Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 VaccinesEpidemiology, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine EffectivenessAmerican Journal of Epidemiology, 2016
- Invited Commentary: Beware the Test-Negative DesignAmerican Journal of Epidemiology, 2016